Latest Adaptive Biotechnologies Corporation Stories

SEATTLE, May 9, 2013 /PRNewswire/ -- Adaptive Biotechnologies announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology. (Logo: http://photos.prnewswire.com/prnh/20120103/SF28632LOGO) Under the collaboration, Adaptive will use its proprietary immune profiling assay, immunoSEQ, to identify potential biomarkers that may inform about drug response. The immunoSEQ assay uses high throughput...

SEATTLE, Dec. 6, 2012 /PRNewswire/ -- Adaptive Biotechnologies, a leading provider of next-generation sequencing assays for the adaptive immune system, today introduced clonoSEQ, a clinical assay to measure minimal residual disease (MRD) in a range of blood-based cancers that is significantly more sensitive than today's most common tests. clonoSEQ will be available for widespread clinical use by mid-2013. "This new approach of using high throughput sequencing to detect and...

SEATTLE, May 16, 2012 /PRNewswire/ -- Adaptive Biotechnologies Corporation, a leading provider of next-generation sequencing assays for the adaptive immune system, announced today results from the first head-to-head comparison of high throughput sequencing (HTS) using immunoSEQ(TM) and traditional flow cytometry. The study, which was conducted in collaboration with Fred Hutchinson Cancer Research Center and the University of Washington Department of Laboratory Medicine, was...

SEATTLE, Jan. 3, 2012 /PRNewswire/ -- Adaptive TCR Corporation, a leading provider of next generation sequencing assays for the adaptive immune system marketed under the brand name immunoSEQ, announced today it has changed its name to Adaptive Biotechnologies Corporation effective immediately. (Logo: http://photos.prnewswire.com/prnh/20120103/SF28632LOGO) The name change reflects the expanded capabilities of the company's original immune profiling business as well as the...